Millendo Therapeutics to Present at Prader-Willi Syndrome Conferences

ANN ARBOR, Mich.--(BUSINESS WIRE)--Millendo Therapeutics, Inc. (Nasdaq: MLND), a clinical-stage biopharmaceutical company developing novel treatments primarily for orphan endocrine diseases, today announced that it will participate in oral presentations and poster sessions at two upcoming Prader-Willi syndrome (PWS) conferences. Presentations will be made by both PWS clinician thought leaders and Millendo scientific personnel, and will feature a trial-in-progress report on Millendo’s pivotal Phase 2b/3 clinical trial of livoletide for PWS (ZEPHYR), a comprehensive review of livoletide’s preclinical studies up to 9 months in duration, data on livoletide in obese and non-obese populations and concomitant use with growth hormone therapy, and new research insights from claims database analyses on the prevalence of comorbidities and overall outcomes in the PWS population.